Business
Bioasis Appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as Chair of the Board of Directors
Bioasis Appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as Chair of the Board of Directors.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n BIOASIS \n TECHNOLOGIES, INC. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical \n company with a proprietary blood-brain barrier platform technology \n focused on development of therapeutics for the treatment of brain \n cancers and neurodegenerative diseases, today announced that Dr. Deborah \n Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE, has been appointed as chair \n of the board of directors. She takes over from former board chair and \n chief executive officer Rob Hutchison, who retired on Dec. 4, 2017. Dr. \n Rathjen will continue to serve as a member of the compensation committee \n and has stepped down as chair of the audit committee, but will continue \n to serve as a member of the audit committee. A new audit committee chair \n will be appointed at a later date.\n \n\nThis press release features multimedia. View the full release here: \nhttps://www.businesswire.com/news/home/20180321005435/en/\n\n \n \n Bioasis appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as chair of the board of directors. Dr. Rathjen is the chief executive officer and managing director of Bionomics in Adelaide, Australia. Dr. Rathjen joined the Bioasis board of directors in September 2017. (Photo: Business Wire) \n\n\n \n “We are absolutely delighted that Dr. Rathjen is the new chair of our \n board,” said Mark Day, Ph.D., president and chief executive officer, \n Bioasis. “I first met Deborah in 2013 when I was heading neuroscience \n business development at Bristol Myers Squibb and was immediately \n impressed with her drive, enthusiasm and passion for science and drug \n development. Deborah is an inspirational leader and has built an amazing \n company at Bionomics with a really energized and synergistic team who \n have accomplished a leading CNS pipeline. From business a development \n perspective, Deborah has a strategic collaboration with Merck in \n Alzheimer’s Disease and under her leadership, Bionomics has developed \n exciting phase 2 studies in anxiety disorders and in post-traumatic \n stress disorder. Deborah’s expertise in running public companies paired \n with her scientific prowess makes her the ideal chair for our company at \n this transformational time.”\n \n \n “I look forward to working with my fellow board members and the Bioasis \n executive team to help guide Bio...